{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T23:27:38Z","timestamp":1687908458795},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,12,1]]},"DOI":"10.1093\/jac\/dki367","type":"journal-article","created":{"date-parts":[[2005,10,26]],"date-time":"2005-10-26T07:13:57Z","timestamp":1130310837000},"page":"1074-1080","source":"Crossref","is-referenced-by-count":11,"title":["Clindamycin and quinolone therapy for Bacillus anthracis Sterne infection in 60Co-gamma-photon-irradiated and sham-irradiated mice"],"prefix":"10.1093","volume":"56","author":[{"given":"I.","family":"Brook","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Germana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. E.","family":"Giraldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. D.","family":"Camp-Hyde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. L.","family":"Bolduc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A.","family":"Foriska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. B.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. H.","family":"Thakar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. O.","family":"Shoemaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. E.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. D.","family":"Ledney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,10,20]]},"reference":[{"key":"key\n\t\t\t\t20171010151033_B1","doi-asserted-by":"crossref","unstructured":"Dewan PK, Fry AM, Laserson K et al. Inhalational anthrax outbreak among postal workers, Washington, D.C., 2001. Emerg Infect Dis2002; 8: 1066.","DOI":"10.3201\/eid0810.020330"},{"key":"key\n\t\t\t\t20171010151033_B2","doi-asserted-by":"crossref","unstructured":"Christopher GW, Cieslak TJ, Pavlin JA et al. Biological warfare. A historical perspective. JAMA1997; 278: 412\u201317.","DOI":"10.1001\/jama.278.5.412"},{"key":"key\n\t\t\t\t20171010151033_B3","doi-asserted-by":"crossref","unstructured":"Franz DR, Jahrling PB, Friedlander AM et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA1997; 278: 399\u2013411.","DOI":"10.1001\/jama.278.5.399"},{"key":"key\n\t\t\t\t20171010151033_B4","doi-asserted-by":"crossref","unstructured":"Inglesby TV, Henderson DA, Bartlett JG et al. Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA1999; 281: 1735\u201345.","DOI":"10.1001\/jama.281.18.1735"},{"key":"key\n\t\t\t\t20171010151033_B5","doi-asserted-by":"crossref","unstructured":"Pile JC, Malone JD, Eitzen EM et al. Anthrax as a potential biological warfare agent. Arch Intern Med1998; 158: 429\u201334.","DOI":"10.1001\/archinte.158.5.429"},{"key":"key\n\t\t\t\t20171010151033_B6","unstructured":"World Health Organization. Health Aspects of Chemical and Biological Weapons: A Report of a WHO Group of Consultants. Geneva: World Health Organization, 1970."},{"key":"key\n\t\t\t\t20171010151033_B7","unstructured":"Alper T. Cellular Radiobiology. New York: Cambridge University Press, 1979."},{"key":"key\n\t\t\t\t20171010151033_B8","doi-asserted-by":"crossref","unstructured":"Brook I, Elliott TB, Harding RA et al. Susceptibility of irradiated mice to Bacillus anthracis Sterne by the intratracheal route of infection. J Med Microbiol2001; 50: 702\u201311.","DOI":"10.1099\/0022-1317-50-8-702"},{"key":"key\n\t\t\t\t20171010151033_B9","doi-asserted-by":"crossref","unstructured":"Falgas ME, Gorbach SL. Clindamycin and metronidazole. Med Clin North Am1995; 79: 845\u201352.","DOI":"10.1016\/S0025-7125(16)30043-8"},{"key":"key\n\t\t\t\t20171010151033_B10","doi-asserted-by":"crossref","unstructured":"Athamna A, Massalha M, Athamna M et al. In vitro susceptibility of Bacillus anthracis to various antibacterial agents and their time-kill activity. J Antimicrob Chemother2004; 53: 247\u201351.","DOI":"10.1093\/jac\/dkh016"},{"key":"key\n\t\t\t\t20171010151033_B11","doi-asserted-by":"crossref","unstructured":"Mohammed MJ, Marston CK, Popovic T et al. Antimicrobial susceptibility testing of Bacillus anthracis: comparison of results obtained by using the National Committee for Clinical Laboratory Standards broth microdilution reference and Etest agar gradient diffusion methods. J Clin Microbiol2002; 40: 1902\u20137.","DOI":"10.1128\/JCM.40.6.1902-1907.2002"},{"key":"key\n\t\t\t\t20171010151033_B12","doi-asserted-by":"crossref","unstructured":"Stevens DL, Bryant AE, Hackett SP. Antibiotic effects on bacterial viability, toxin production, and host response. Clin Infect Dis1995; 20: S154\u20137.","DOI":"10.1093\/clinids\/20.Supplement_2.S154"},{"key":"key\n\t\t\t\t20171010151033_B13","doi-asserted-by":"crossref","unstructured":"Gemmell CG, Peterson PK, Schmeling D et al. Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin. J Clin Invest1981; 67: 1249\u201356.","DOI":"10.1172\/JCI110152"},{"key":"key\n\t\t\t\t20171010151033_B14","unstructured":"Gemmell CG, Lambe DW, Santos JI. The influence of clindamycin on the host-parasite relationship. In: Clindamycin in the Treatment of Human Infections. Michigan: Pharmacia & Upjohn Company, 1997; 3-10\u20133-12."},{"key":"key\n\t\t\t\t20171010151033_B15","doi-asserted-by":"crossref","unstructured":"Zhao X, Wang JY, Xu C. Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones. Antimicrob Agents Chemother1998; 42: 956\u20138.","DOI":"10.1128\/AAC.42.4.956"},{"key":"key\n\t\t\t\t20171010151033_B16","doi-asserted-by":"crossref","unstructured":"Friedlander AM, Welkos SL, Pitt ML et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis1993; 167: 1239\u201343.","DOI":"10.1093\/infdis\/167.5.1239"},{"key":"key\n\t\t\t\t20171010151033_B17","doi-asserted-by":"crossref","unstructured":"Brook I, Elliott TB, Pryor HI et al. In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones. Int J Antimicrob Agents2001; 18: 559\u201362.","DOI":"10.1016\/S0924-8579(01)00464-2"},{"key":"key\n\t\t\t\t20171010151033_B18","doi-asserted-by":"crossref","unstructured":"Price LB, Vogler A, Pearson T et al. In vitro selection and characterization of Bacillus anthracis mutants with high-level resistance to ciprofloxacin. Antimicrob Agents Chemother2003; 47: 2362\u20135.","DOI":"10.1128\/AAC.47.7.2362-2365.2003"},{"key":"key\n\t\t\t\t20171010151033_B19","doi-asserted-by":"crossref","unstructured":"Casin I. Fluoroquinolone resistance linked to GyrA, GyrB, and ParC mutations in Salmonella enterica Typhimurium isolates in humans. Emerg Infect Dis2003; 9: 1455\u20137.","DOI":"10.3201\/eid0911.030317"},{"key":"key\n\t\t\t\t20171010151033_B20","unstructured":"Esposito S, Gupta A, Thadepalli H. In vitro synergy of ciprofloxacin and three other antibiotics against Bacteroides fragilis. Drugs Exp Clin Res1987; 13: 489\u201392."},{"key":"key\n\t\t\t\t20171010151033_B21","doi-asserted-by":"crossref","unstructured":"Neu HC. Synergy and antagonism of combinations with quinolones Eur J Clin Microbiol Infect Dis1991; 10: 255\u201361.","DOI":"10.1007\/BF01966998"},{"key":"key\n\t\t\t\t20171010151033_B22","unstructured":"Centers for Disease Control and Prevention. Additional options for preventive treatment for persons exposed to inhalational anthrax. Morb Mortal Wkly Rep2001; 50: 1142\u201351."},{"key":"key\n\t\t\t\t20171010151033_B23","doi-asserted-by":"crossref","unstructured":"Athamna A, Athamna M, Nura A et al. Is in vitro antibiotic combination more effective than single-drug therapy against anthrax? Antimicrob Agents Chemother2005; 49: 1323\u20135.","DOI":"10.1128\/AAC.49.4.1323-1325.2005"},{"key":"key\n\t\t\t\t20171010151033_B24","unstructured":"National Research Council. Guide for the care and use of laboratory animals. In: Institute of Laboratory Animal Resources Commission on Life Sciences. Washington, DC: National Academy Press, 1996."},{"key":"key\n\t\t\t\t20171010151033_B25","doi-asserted-by":"crossref","unstructured":"Schaeffer P, Millet J, Aubert JP. Catabolic repression of bacterial sporulation. Proc Natl Acad Sci USA1965; 54: 704\u201311.","DOI":"10.1073\/pnas.54.3.704"},{"key":"key\n\t\t\t\t20171010151033_B26","unstructured":"National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically\u2014Third Edition: Approved Standard M7-A3. NCCLS, Villanova, PA, 1993."},{"key":"key\n\t\t\t\t20171010151033_B27","unstructured":"Saffiotti W, Cefis F, Kolb LH. A method for the experimental induction of bronchogenic carcinoma. Cancer Res1968; 28: 104\u201324."},{"key":"key\n\t\t\t\t20171010151033_B28","unstructured":"Yehezkelli Y, Dushnitsky T, Hourvitz A. Radiation terrorism\u2014the medical challenge. Isr Med Assoc J2002; 4: 530\u20134."},{"key":"key\n\t\t\t\t20171010151033_B29","doi-asserted-by":"crossref","unstructured":"Onyeji CO, Khanh QB, Owens RC et al. Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia. Int J Antimicrob Agents1999; 12: 107\u201314.","DOI":"10.1016\/S0924-8579(98)00087-9"},{"key":"key\n\t\t\t\t20171010151033_B30","doi-asserted-by":"crossref","unstructured":"Koh AY, Priebe GP, Pier GB. Virulence of Pseudomonas aeruginosa in a murine model of gastrointestinal colonization and dissemination in neutropenia. Infect Immun2005; 73: 2262\u201372.","DOI":"10.1128\/IAI.73.4.2262-2272.2005"},{"key":"key\n\t\t\t\t20171010151033_B31","doi-asserted-by":"crossref","unstructured":"Ernst EJ, Klepser ME, Petzold CR et al. Evaluation of survival and pharmacodynamic relationships for five fluoroquinolones in a neutropenic murine model of pneumococcal lung infection. Pharmacotherapy2002; 22: 463\u201370.","DOI":"10.1592\/phco.22.7.463.33670"},{"key":"key\n\t\t\t\t20171010151033_B32","doi-asserted-by":"crossref","unstructured":"Brook I, MacVittie TJ, Walker RI. Effect of radiation dose on the recovery of aerobic and anaerobic bacteria from mice. Can J Microbiol1986; 32: 719\u201322.","DOI":"10.1139\/m86-130"},{"key":"key\n\t\t\t\t20171010151033_B33","doi-asserted-by":"crossref","unstructured":"Hirata N, Hiramatsu K, Kishi K et al. Pretreatment of mice with clindamycin improves survival of endotoxic shock by modulating the release of inflammatory cytokines. Antimicrob Agents Chemother2001; 45: 2638\u201342.","DOI":"10.1128\/AAC.45.9.2638-2642.2001"},{"key":"key\n\t\t\t\t20171010151033_B34","doi-asserted-by":"crossref","unstructured":"Elliott TB, Brook I, Harding RA et al. Antimicrobial therapy for Bacillus anthracis-induced mixed infection in 60Co-\u03b3-irradiated mice. Antimicrob Agents Chemother2002; 46: 3463\u201371.","DOI":"10.1128\/AAC.46.11.3463-3471.2002"},{"key":"key\n\t\t\t\t20171010151033_B35","doi-asserted-by":"crossref","unstructured":"Brook I, Elliott TB. Quinolone therapy in the prevention of mortality after irradiation. Radiat Res1991; 128: 100\u20133.","DOI":"10.2307\/3578072"},{"key":"key\n\t\t\t\t20171010151033_B36","doi-asserted-by":"crossref","unstructured":"Knudson GB. Treatment of anthrax in man: history and current concepts. Mil Med1986; 151: 71\u20137.","DOI":"10.1093\/milmed\/151.2.71"},{"key":"key\n\t\t\t\t20171010151033_B37","doi-asserted-by":"crossref","unstructured":"Boeckh M, Lode H, Deppermann KM et al. Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole. Antimicrob Agents Chemother1990; 34: 2407\u201314.","DOI":"10.1128\/AAC.34.12.2407"},{"key":"key\n\t\t\t\t20171010151033_B38","doi-asserted-by":"crossref","unstructured":"Jernigan JA, Stephens DS, Ashford DA et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis2001; 7: 933\u201344.","DOI":"10.3201\/eid0706.010604"},{"key":"key\n\t\t\t\t20171010151033_B39","doi-asserted-by":"crossref","unstructured":"Blondeau JM, Laskowski R, Bjarnason J et al. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms. Int J Antimicrob Agents2000; 14: 45\u201350.","DOI":"10.1016\/S0924-8579(99)00143-0"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/56\/6\/1074\/2259613\/dki367.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T13:47:11Z","timestamp":1586526431000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/56\/6\/1074\/752979\/Clindamycin-and-quinolone-therapy-for-Bacillus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,20]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2005,10,20]]},"published-print":{"date-parts":[[2005,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dki367","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,12]]},"published":{"date-parts":[[2005,10,20]]}}}